Severe pemphigus vulgaris and cervical carcinoma treated with anti PD1 antibody pembrolizumab: A therapeutic dilemma?
Abstract Managing autoimmune diseases (AIDs) in the context of malignancies and vice versa is an intricate challenge for clinicians. Immunotherapies stimulate antitumor immune responses by blocking checkpoint molecules such as PD1. However, new onset or aggravation of autoimmune reactions are freque...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-03-01
|
| Series: | JEADV Clinical Practice |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/jvc2.589 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850099095802216448 |
|---|---|
| author | Sophia Wasserer Kristine Mayer Svenja Rupp Tilo Biedermann Oliver J. Stoetzer Moritz Hamann Felix Lauffer |
| author_facet | Sophia Wasserer Kristine Mayer Svenja Rupp Tilo Biedermann Oliver J. Stoetzer Moritz Hamann Felix Lauffer |
| author_sort | Sophia Wasserer |
| collection | DOAJ |
| description | Abstract Managing autoimmune diseases (AIDs) in the context of malignancies and vice versa is an intricate challenge for clinicians. Immunotherapies stimulate antitumor immune responses by blocking checkpoint molecules such as PD1. However, new onset or aggravation of autoimmune reactions are frequent side effects of immunotherapies. Pemphigus vulgaris (PV) is a severe blistering autoimmune‐mediated skin disease requiring immune‐suppressive therapy. Here, we present a case, wherein a patient with severe PV underwent rituximab therapy, while simultaneously a newly diagnosed advanced cervical carcinoma was treated with pembrolizumab. |
| format | Article |
| id | doaj-art-fed5c43554664a66b92b1a3c9577eca8 |
| institution | DOAJ |
| issn | 2768-6566 |
| language | English |
| publishDate | 2025-03-01 |
| publisher | Wiley |
| record_format | Article |
| series | JEADV Clinical Practice |
| spelling | doaj-art-fed5c43554664a66b92b1a3c9577eca82025-08-20T02:40:33ZengWileyJEADV Clinical Practice2768-65662025-03-014125626110.1002/jvc2.589Severe pemphigus vulgaris and cervical carcinoma treated with anti PD1 antibody pembrolizumab: A therapeutic dilemma?Sophia Wasserer0Kristine Mayer1Svenja Rupp2Tilo Biedermann3Oliver J. Stoetzer4Moritz Hamann5Felix Lauffer6Department of Dermatology and Allergy Technical University of Munich Munich GermanyDepartment of Dermatology and Allergy Technical University of Munich Munich GermanyDepartment of Dermatology and Allergy Technical University of Munich Munich GermanyDepartment of Dermatology and Allergy Technical University of Munich Munich GermanyMedical Center for Hematology and Oncology Munich GermanyDepartment of Gynecology Red Cross Hospital Munich (Taxisstr.) Munich GermanyDepartment of Dermatology and Allergy Technical University of Munich Munich GermanyAbstract Managing autoimmune diseases (AIDs) in the context of malignancies and vice versa is an intricate challenge for clinicians. Immunotherapies stimulate antitumor immune responses by blocking checkpoint molecules such as PD1. However, new onset or aggravation of autoimmune reactions are frequent side effects of immunotherapies. Pemphigus vulgaris (PV) is a severe blistering autoimmune‐mediated skin disease requiring immune‐suppressive therapy. Here, we present a case, wherein a patient with severe PV underwent rituximab therapy, while simultaneously a newly diagnosed advanced cervical carcinoma was treated with pembrolizumab.https://doi.org/10.1002/jvc2.589cervical cancerICIImmunotherapyirAEPD1 Inhibitionpembrolizumab |
| spellingShingle | Sophia Wasserer Kristine Mayer Svenja Rupp Tilo Biedermann Oliver J. Stoetzer Moritz Hamann Felix Lauffer Severe pemphigus vulgaris and cervical carcinoma treated with anti PD1 antibody pembrolizumab: A therapeutic dilemma? JEADV Clinical Practice cervical cancer ICI Immunotherapy irAE PD1 Inhibition pembrolizumab |
| title | Severe pemphigus vulgaris and cervical carcinoma treated with anti PD1 antibody pembrolizumab: A therapeutic dilemma? |
| title_full | Severe pemphigus vulgaris and cervical carcinoma treated with anti PD1 antibody pembrolizumab: A therapeutic dilemma? |
| title_fullStr | Severe pemphigus vulgaris and cervical carcinoma treated with anti PD1 antibody pembrolizumab: A therapeutic dilemma? |
| title_full_unstemmed | Severe pemphigus vulgaris and cervical carcinoma treated with anti PD1 antibody pembrolizumab: A therapeutic dilemma? |
| title_short | Severe pemphigus vulgaris and cervical carcinoma treated with anti PD1 antibody pembrolizumab: A therapeutic dilemma? |
| title_sort | severe pemphigus vulgaris and cervical carcinoma treated with anti pd1 antibody pembrolizumab a therapeutic dilemma |
| topic | cervical cancer ICI Immunotherapy irAE PD1 Inhibition pembrolizumab |
| url | https://doi.org/10.1002/jvc2.589 |
| work_keys_str_mv | AT sophiawasserer severepemphigusvulgarisandcervicalcarcinomatreatedwithantipd1antibodypembrolizumabatherapeuticdilemma AT kristinemayer severepemphigusvulgarisandcervicalcarcinomatreatedwithantipd1antibodypembrolizumabatherapeuticdilemma AT svenjarupp severepemphigusvulgarisandcervicalcarcinomatreatedwithantipd1antibodypembrolizumabatherapeuticdilemma AT tilobiedermann severepemphigusvulgarisandcervicalcarcinomatreatedwithantipd1antibodypembrolizumabatherapeuticdilemma AT oliverjstoetzer severepemphigusvulgarisandcervicalcarcinomatreatedwithantipd1antibodypembrolizumabatherapeuticdilemma AT moritzhamann severepemphigusvulgarisandcervicalcarcinomatreatedwithantipd1antibodypembrolizumabatherapeuticdilemma AT felixlauffer severepemphigusvulgarisandcervicalcarcinomatreatedwithantipd1antibodypembrolizumabatherapeuticdilemma |